Stock AnalizAstrazeneca PLC AZN
Biotechnology: Pharmaceutical Preparations · IPO 2026 · data as of November 13, 2026
Astrazeneca PLC (AZN) is a healthcare company listed in the US with a market value of about $286.0B. In the twelve months to September 30, 2026 it had revenue of $62.4B and net income of $11.0B, a net margin of 17.7%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is track record (4/5); the weakest is value (1/5).
Key numbers: a P/E of 26.1, a price to free cash flow of 46.9, 5-year revenue growth of 17% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 38% below the current price.
Score: 2.8 / 5
Checks passed
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.4B | $58.7B | $54.1B | $45.8B | $44.4B | $37.4B | $26.6B | $24.4B | $22.1B | $22.5B | $23.0B |
| Net income | $11.0B | $10.2B | $7.0B | $6.0B | $3.3B | $112M | $3.2B | $1.3B | $2.2B | $3.0B | $3.5B |
| Free cash flow | $6.1B | $11.8B | $9.9B | $9.0B | $8.7B | $4.9B | $3.8B | $2.0B | $1.6B | $2.3B | $2.7B |
| EPS (diluted) | $7.06 | $6.59 | $4.54 | $3.84 | $2.12 | $0.07 | $2.06 | $0.86 | $1.39 | $1.94 | $2.26 |
| Net margin | 17.7% | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
| ROIC | — | 14.5% | 11.4% | 10.4% | 4.5% | 1.2% | 11.5% | 7.4% | 8.5% | 8.9% | 14.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $208.07, 13% above the current price; targets range from $158.00 to $240.00; the consensus rating is “Buy”; expected EPS is $10.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Astrazeneca’s P/E ratio?
About 26.1, based on the last twelve months of diluted earnings per share (forward P/E about 16.5).
Is Astrazeneca stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 38% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Astrazeneca pay a dividend?
Yes. The dividend yield is about 1.73%, and it has paid dividends for 10 years in our data.
Is Astrazeneca a good stock to buy?
We do not give buy or sell advice. Astrazeneca scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.